89 completed, 42 active not recruiting, 30 terminated, 20 recruiting. 113 Phase 2, 64 Phase 1, 43 Phase 3, 14 Not applicable, 4 Early Phase 1.
Follow this drug Literature Review of Intensity-Modulated Radiation Therapy trials Research Report on Intensity-Modulated Radiation Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Radiation After Surgery to Observation After Surgery in Patients With Clinical Low-Risk, Molecular High-Risk Meningioma, and Evaluating Observation After Surgery in Patients With Clinical and Molecular Low-Risk Meningioma Patient Observation, Magnetic Resonance Imaging, Biospecimen Collection - Grade 1 Meningioma, Grade 2 Meningioma | Phase 3 | Not yet recruiting | NRG Oncology | 464 | 2027-01-28 | 2026-08-25 |
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography - Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities | Phase 3 | Recruiting | SWOG Cancer Research Network | 296 | 2026-12-02 | 2026-10-13 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment Chemotherapy, Immunotherapy, Intensity-Modulated Radiation Therapy - Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 164 | 2026-10-14 | 2026-10-19 |
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-08-17 |
| Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning - Astrocytoma, IDH-Mutant, Grade 3 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 408 | 2026-06-24 | 2026-10-02 |
| Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Hypofractionated Radiation Therapy, Temozolomide (TMZ) - Advanced Glioblastoma | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 422 | 2026-06-10 | 2026-05-26 |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer Biospecimen Collection, Brachytherapy, Carboplatin - Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 336 | 2025-11-05 | 2026-10-21 |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma Biospecimen Collection, Computed Tomography, Intensity-Modulated Radiation Therapy - Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2025-07-30 | 2026-10-21 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma | Phase 3 | Suspended | National Cancer Institute (NCI) | 420 | 2025-02-18 | 2026-10-20 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection - Basal Ganglia Germinoma, Diabetes Insipidus | Phase 2 | Recruiting | Children's Oncology Group | 240 | 2024-10-22 | 2026-08-25 |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma Biopsy, Biospecimen Collection, Computed Tomography - Retroperitoneal Sarcoma | Phase 1 / Phase 2 | Recruiting | Northwestern University | 28 | 2024-04-02 | 2026-07-07 |
| Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation Toripalimab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor | Phase 2 | Active not recruiting | Sun Yat-sen University | 71 | 2023-12-01 | 2025-12-01 |
| De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA Biospecimen Collection, Cisplatin, Computed Tomography - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 455 | 2023-03-20 | 2026-10-01 |
Showing 20 of 214. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (45) · Head and Neck Neoplasms (23) · Prostatic Neoplasms (16) · Glioblastoma (13) · Oropharyngeal Neoplasms (13) · Carcinoma, Non-Small-Cell Lung (11) · Gliosarcoma (11) · Astrocytoma (10) · Laryngeal Neoplasms (10) · Hypopharyngeal Neoplasms (9) · Mouth Neoplasms (9) · Tongue Neoplasms (9) · Carcinoma (8) · Nasopharyngeal Carcinoma (8) · Rectal Neoplasms (8)
National Cancer Institute (NCI) (36) · NRG Oncology (15) · City of Hope Medical Center (13) · Radiation Therapy Oncology Group (13) · M.D. Anderson Cancer Center (10) · Mayo Clinic (10) · ECOG-ACRIN Cancer Research Group (6) · Albert Einstein College of Medicine (5) · Sun Yat-sen University (5) · University of Washington (5) · Children's Oncology Group (4) · Ohio State University Comprehensive Cancer Center (4) · Virginia Commonwealth University (4) · Abramson Cancer Center at Penn Medicine (3) · Alliance for Clinical Trials in Oncology (3)
United States (176) · Canada (39) · China (13) · Puerto Rico (7) · Australia (6) · Hong Kong (6) · Israel (5) · Saudi Arabia (4) · Singapore (4) · Switzerland (4) · United Kingdom (4) · Japan (3) · South Korea (3) · Belgium (2) · France (2)
Steven H Lin (3) · Anna Pawlowska (2) · Anuja Jhingran, MD (2) · Joseph Rosenthal, MD (2) · Loren K Mell (2) · Mercedes Porosnicu, MD (2) · Nabil F Saba (2) · Neha Vapiwala (2) · Oliver Sartor, MD (2) · Robert Ferris (2) · Salma Jabbour, MD (2) · Akila Viswanathan (1) · Akiva Novetsky, MD (1) · Alejandro Sanchez (1) · Alexander Colevas (1)
PMID 25057165, PMID 41343184, PMID 14759776, PMID 15800321, PMID 16425991, PMID 16515704, PMID 20381270, PMID 21599590, PMID 22178121, PMID 22543211, PMID 22811078, PMID 23460709, PMID 24064970, PMID 24139225, PMID 24309981, PMID 24380758, PMID 24438695, PMID 24533532, PMID 24552317, PMID 24991715, PMID 25105369, PMID 25113840, PMID 25154822, PMID 25349290, PMID 25633805, PMID 25752384, PMID 25847373, PMID 25964250, PMID 26951097, PMID 27084653, PMID 27701653, PMID 27727066, PMID 27930762, PMID 28006059, PMID 28086942, PMID 28434660, PMID 29346519, PMID 29528761, PMID 29868473, PMID 29989857, PMID 30102205, PMID 30449625, PMID 30548235, PMID 30995174, PMID 31104905, PMID 31163012, PMID 31420360, PMID 31545689, PMID 31681600, PMID 31912685
U10CA180868 (31), U10CA021661 (11), U10CA180820 (9), P30CA033572 (6), P30CA013330 (5), P30CA015083 (4), U10CA180886 (4), P30CA015704 (3), P30CA016059 (3), P30CA072720 (3), U10CA027469 (3), U10CA098543 (3), UG1CA189867 (3), P30CA012197 (2), P30CA043703 (2)